- Home
- LBRDK vs LEGN Comparison
LBRDK vs LEGN Comparison
Compare LBRDK & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBRDK | LEGN |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LBRDK | LEGN |
|---|---|---|
| Price | $50.95 | $18.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $63.08 |
| AVG Volume (30 Days) | 777.5K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.19 |
| Revenue Next Year | $109.28 | $33.29 |
| P/E Ratio | $10.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.10 | $16.24 |
| 52 Week High | $104.00 | $45.30 |
Technical Indicators
Market Signals| Indicator | LBRDK | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.91 | 48.10 |
| Support Level | $48.17 | $17.46 |
| Resistance Level | $55.26 | $19.36 |
| Average True Range (ATR) | 1.83 | 0.71 |
| MACD | 0.15 | 0.07 |
| Stochastic Oscillator | 56.77 | 51.69 |
Price Performance
Historical ComparisonAbout LBRDK Liberty Broadband Corporation Class C
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.